...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: A fair and optimistic write up on BETonMACE
  1. When statistical tests compare data from two groups, the calculation takes account of the sample sizes. Nevertheless, results from small samples are always considered with caution. Equally important will be whether the low cognitive function subjects turn out to be well matched for factors known to influence it (e.g., age). If a significant difference existed between the placebo and ABL groups in BETonMACE, my guess is the FDA would probably request a Phase 3 study in low cog func patients, possibly plus fast tracking considering the magnitude of the dementia problem and the absence of any effective therapy.
Share
New Message
Please login to post a reply